{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:07Z","timestamp":1765546147011},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/fpc.0000000000000245","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T17:06:39Z","timestamp":1474131999000},"page":"517-525","source":"Crossref","is-referenced-by-count":34,"title":["MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"26","author":[{"given":"Leire","family":"Iparraguirre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Gutierrez-Camino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maitane","family":"Umerez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idoia","family":"Martin-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Astigarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Navajas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagore","family":"Garcia de Andoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Africa","family":"Garcia-Orad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210213","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.canep.2010.06.020","article-title":"Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study","volume":"34","author":"Johnston","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"R2-5-20210213","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0929-6646(10)60123-4","article-title":"Recent research advances in childhood acute lymphoblastic leukemia","volume":"109","author":"Pui","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"R3-5-20210213","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","article-title":"Concepts in use of high-dose methotrexate therapy","volume":"42","author":"Treon","year":"1996","journal-title":"Clin Chem"},{"key":"R4-5-20210213","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/tpj.2011.25","article-title":"Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia","volume":"12","author":"Salazar","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"R5-5-20210213","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.14.106","article-title":"Pharmacogenetics of childhood acute lymphoblastic leukemia","volume":"15","author":"Lopez-Lopez","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R7-5-20210213","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevi\u00f1o","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-5-20210213","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"R9-5-20210213","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-12-580001","article-title":"Inherited genetic variation in childhood acute lymphoblastic leukemia","volume":"125","author":"Moriyama","year":"2015","journal-title":"Blood"},{"key":"R10-5-20210213","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":"Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia","volume":"57","author":"Lopez-Lopez","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R11-5-20210213","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"R12-5-20210213","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","article-title":"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia","volume":"121","author":"Radtke","year":"2013","journal-title":"Blood"},{"key":"R13-5-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","article-title":"Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia","volume":"23","author":"Lopez-Lopez","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R14-5-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"R15-5-20210213","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood.V100.10.3832","article-title":"Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia","volume":"100","author":"Laverdi\u00e8re","year":"2002","journal-title":"Blood"},{"key":"R16-5-20210213","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molmed.2011.04.003","article-title":"MicroRNA pharmacogenomics: post-transcriptional regulation of drug response","volume":"17","author":"Rukov","year":"2011","journal-title":"Trends Mol Med"},{"key":"R17-5-20210213","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-14-2817","article-title":"Polymorphisms in MIR27A associated with early-onset toxicity in fluoropyrimidine-based chemotherapy","volume":"21","author":"Amstutz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R18-5-20210213","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/ijc.30014","article-title":"Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity","volume":"138","author":"Meulendijks","year":"2016","journal-title":"Int J Cancer"},{"key":"R19-5-20210213","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jcla.21544","article-title":"Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population","volume":"26","author":"Zhan","year":"2012","journal-title":"J Clin Lab Anal"},{"key":"R20-5-20210213","doi-asserted-by":"crossref","first-page":"e91261","DOI":"10.1371\/journal.pone.0091261","article-title":"Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia","volume":"9","author":"L\u00f3pez-L\u00f3pez","year":"2014","journal-title":"PLoS One"},{"key":"R21-5-20210213","doi-asserted-by":"crossref","first-page":"D68","DOI":"10.1093\/nar\/gkt1181","article-title":"miRBase: annotating high confidence microRNAs using deep sequencing data","volume":"42","author":"Kozomara","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"R22-5-20210213","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2217\/pgs.14.97","article-title":"Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies","volume":"15","author":"Suthandiram","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R24-5-20210213","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"key":"R25-5-20210213","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jbi.2011.05.002","article-title":"miRWalk \u2013 database: prediction of possible miRNA binding sites by \u2018walking\u2019 the genes of three genomes","volume":"44","author":"Dweep","year":"2011","journal-title":"J Biomed Inform"},{"key":"R26-5-20210213","doi-asserted-by":"crossref","first-page":"W70","DOI":"10.1093\/nar\/gkn188","article-title":"The Vienna RNA websuite","volume":"36","author":"Gruber","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"R27-5-20210213","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/humu.21641","article-title":"Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis","volume":"33","author":"Gong","year":"2012","journal-title":"Hum Mutat"},{"key":"R28-5-20210213","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/jm8011323","article-title":"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry","volume":"52","author":"Deng","year":"2009","journal-title":"J Med Chem"},{"key":"R29-5-20210213","doi-asserted-by":"crossref","first-page":"C1669","DOI":"10.1152\/ajpcell.00202.2007","article-title":"Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction","volume":"293","author":"Qiu","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"R30-5-20210213","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/mol.108.045443","article-title":"The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier","volume":"74","author":"Zhao","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R31-5-20210213","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-800223-0.00004-9","article-title":"Biology of the major facilitative folate transporters SLC19A1 and SLC46A1","volume":"73","author":"Hou","year":"2014","journal-title":"Curr Top Membr"},{"key":"R32-5-20210213","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4161\/cbt.22020","article-title":"The human proton-coupled folate transporter: biology and therapeutic applications to cancer","volume":"13","author":"Desmoulin","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"R33-5-20210213","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","article-title":"Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption","volume":"127","author":"Qiu","year":"2006","journal-title":"Cell"},{"key":"R34-5-20210213","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10038-006-0096-z","article-title":"Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma","volume":"52","author":"Imanishi","year":"2007","journal-title":"J Hum Genet"},{"key":"R35-5-20210213","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.mph.0000198269.61948.90","article-title":"Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma","volume":"28","author":"Shimasaki","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"R36-5-20210213","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","article-title":"Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma","volume":"67","author":"Faganel Kotnik","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"R37-5-20210213","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12032-014-0062-0","article-title":"Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia","volume":"31","author":"Wang","year":"2014","journal-title":"Med Oncol"},{"key":"R38-5-20210213","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/jpet.106.104364","article-title":"Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants","volume":"318","author":"Badagnani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R39-5-20210213","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-015-3552-7","article-title":"High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial","volume":"153","author":"Callens","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"R40-5-20210213","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1208\/s12248-013-9515-1","article-title":"Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2","volume":"15","author":"Zhou","year":"2013","journal-title":"AAPS J"},{"key":"R41-5-20210213","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.106.110379","article-title":"Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2\/ABCC2- and MRP4\/ABCC4-mediated methotrexate transport","volume":"320","author":"El-Sheikh","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R42-5-20210213","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.V133595","article-title":"The MRP4\/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP","volume":"13","author":"Van Aubel","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R43-5-20210213","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/jhg.2009.79","article-title":"Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients","volume":"54","author":"Low","year":"2009","journal-title":"J Hum Genet"},{"key":"R44-5-20210213","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","article-title":"Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3","volume":"17","author":"Nicoletti","year":"2012","journal-title":"Oncologist"},{"key":"R45-5-20210213","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/0008-5472.CAN-07-6790","article-title":"Transporter-mediated protection against thiopurine-induced hematopoietic toxicity","volume":"68","author":"Krishnamurthy","year":"2008","journal-title":"Cancer Res"},{"key":"R46-5-20210213","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2008-11-191098","article-title":"Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia","volume":"114","author":"Ansari","year":"2009","journal-title":"Blood"},{"key":"R47-5-20210213","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/tpj.2014.63","article-title":"Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia","volume":"15","author":"den Hoed","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"R48-5-20210213","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ddr.21278","article-title":"Validated microRNA target databases: an evaluation","volume":"76","author":"Lee","year":"2015","journal-title":"Drug Dev Res"},{"key":"R49-5-20210213","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/nar\/gkv1221","article-title":"Bioinformatic tools for microRNA dissection","volume":"44","author":"Akhtar","year":"2016","journal-title":"Nucleic Acids Res"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T18:20:46Z","timestamp":1657304446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201611000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000245","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}